Abstract
Background The tremendous burden of malaria has led to renewed efforts focusing on malaria elimination in high burden countries and has spurred the development of novel tools such as the use of transgenic mosquitoes to modify or suppress vector populations to interrupt transmission. Gene drives offer a pathway to propagate transgenes and their associated phenotypes to future generations more efficiently than the natural 50% probability and could potentially be applied as a vector control method. This study evaluates the role of suppression gene drives within broader intervention strategies, using the sex-ratio distorting driving-Y gene drive as an example.
Method We parameterize a spatially explicit, agent-based, mathematical model to capture malaria transmission in eight representative provinces of the Democratic Republic of the Congo, an operationally complex high-burden setting. We explore the potential impact of integrating driving-Y gene drive mosquitoes in malaria elimination strategies that include existing interventions such as insecticide-treated nets and treatment of clinical cases. An economic evaluation was performed to estimate the cost-effectiveness of gene drives, other interventions, and combinations.
Findings Releases of gene drive mosquitoes were capable of eliminating malaria and were the most cost-effective intervention overall, as long as the drive component was highly effective with at least 95% X-shredding, and associated cost of deployment was below 7.17 $int per person per year.
Interpretation Genetically-based vector control via suppression gene drive could be a cost-effective supplement to traditional malaria interventions for malaria elimination, but tight constraints on drive effectiveness and cost ceilings may prove to limit its operational feasibility.
Funding Federal Ministry for Economic Cooperation and Development via German Academic Exchange Service (DAAD) and the Wellcome Trust.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Federal Ministry for Economic Cooperation and Development via German Academic Exchange Service (DAAD) and the Wellcome Trust.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study received the ethical clearance from ZEF Research Ethics Committee on July 9, 2019.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Abstract updated; Research in context added; Figure 3 and Figure 4 revised; Supplemental file updated; Acknowledgement updated.
Data Availability
Codes on GitHub: gene drive: https://github.com/NaniMet/gene drive dtk-tools: https://github.com/InstituteforDiseaseModeling/dtk-tools EMOD: https://github.com/InstituteforDiseaseModeling/EMOD